Telix Pharmaceuticals Limited (TLX) Balance Sheet
TLX balance sheet, 2025
December 31, 2025 · U.S. dollars$1.77B assets = $1.15B liabilities + $622.3M equity
Both columns are drawn to the same scale: what TLX owns equals what it owes plus shareholders’ equity. Hover a block for its value.
TLX financial health
Descriptive bands, not a rating. Fiscal 2025.
TLX balance sheet trends, 2015–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $17.8M2015 | $1.77B2025 | +150.9%/yr | |
| Total liabilities | $18.0M2015 | $1.15B2025 | +129.5%/yr | |
| Shareholders’ equity | −$213,9342015 | $622.3M2025 | — | |
| Cash & short-term investments | $750,1422015 | $212.5M2025 | +209.4%/yr | |
| Total debt | $1.8M2015 | $699.8M2025 | +230.6%/yr | |
| Net cash (debt) | −$1.0M2015 | −$487.2M2025 | −$486.2M | |
| Working capital | −$3.4M2015 | $147.8M2025 | +$151.2M | |
| Book value per share | −$0.002015 | $1.842025 | — | |
| Current ratio | 0.712015 | 1.432025 | +0.72 | |
| Debt / equity | 0.012017 | 1.122025 | +1.12 | |
| Shares outstanding | 83.3M2015 | 337.9M2025 | +32.3%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
TLX assets
TLX liabilities and equity
TLX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
TLX balance sheet
| 2025 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Cash & short-term investments | $212.5M | $44.6M | $25.8M | $48.8M | $840,886 | $750,142 |
| Cash & equivalents | $212.5M | $44.6M | $25.8M | $48.8M | $840,886 | $750,142 |
| Receivables | $207.3M | $13.0M | $9.0M | $488,831 | $4.3M | $4.0M |
| Inventory | $55.5M | $542,000 | $642,525 | $297,220 | $2.6M | $2.6M |
| Other current assets | $19.4M | $530,000 | $472,305 | $0 | $931,080 | $829,682 |
| Total current assets | $494.8M | $58.7M | $35.9M | $49.5M | $8.7M | $8.1M |
| Property, plant & equipment (net) | $173.2M | $1.9M | $226,171 | $5,389 | $3.2M | $1.6M |
| Goodwill & intangible assets | $888.1M | $46.2M | $39.5M | $1.5M | $1.0M | $1.0M |
| Long-term investments | $3.7M | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $211.1M | $0 | $1.2M | $35,292 | $5.7M | $7.1M |
| Total assets | $1.77B | $102.6M | $76.7M | $51.1M | $18.6M | $17.8M |
| Liabilities | ||||||
| Accounts payable | $107.4M | $7.0M | $3.2M | $275,844 | $2.1M | $1.7M |
| Short-term debt | $28.0M | $490,000 | $1.1M | $345,433 | $4.1M | $1.4M |
| Deferred revenue | $17.2M | $174,637 | $3.6M | — | $1.3M | $1.3M |
| Total current liabilities | $347.0M | $10.6M | $8.2M | $1.5M | $14.3M | $11.5M |
| Long-term debt | $391.9M | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $62.1M | — | — | — | — | — |
| Other long-term liabilities | $409.7M | $21.9M | $15.6M | $332,489 | $6.1M | $6.5M |
| Total liabilities | $1.15B | $32.5M | $23.8M | $1.8M | $20.4M | $18.0M |
| Shareholders' equity | ||||||
| Common stock & paid-in capital | $719.0M | $115.9M | $72.1M | $55.6M | $2,775 | $2,743 |
| Retained earnings (deficit) | −$231.5M | −$48.1M | −$20.2M | −$6.4M | −$33.1M | −$31.6M |
| Accumulated other comprehensive income | $134.8M | $2.2M | $1.1M | $108,998 | −$7.8M | −$7.2M |
| Total shareholders' equity | $622.3M | $70.1M | $52.9M | $49.3M | −$1.8M | −$213,934 |
| Key figures | ||||||
| Total debt | $699.8M | $2.1M | $1.7M | $345,433 | $4.2M | $1.8M |
| Net cash (debt) | −$487.2M | $42.5M | $24.0M | $48.4M | −$3.4M | −$1.0M |
| Working capital | $147.8M | $48.1M | $27.6M | $48.1M | −$5.5M | −$3.4M |
| Tangible book value | −$265.8M | $23.9M | $13.5M | $47.8M | −$2.8M | −$1.2M |
| Book value per share | $1.84 | $0.30 | $0.26 | $0.39 | −$0.01 | −$0.00 |
| Shares outstanding | 337.9M | 233.4M | 202.1M | 128.0M | 128.0M | 83.3M |
| Current ratio | 1.43 | 5.52 | 4.35 | 33.74 | 0.61 | 0.71 |
| Quick ratio | 1.21 | 5.42 | 4.22 | 33.54 | 0.36 | 0.41 |
| Debt / equity | 1.12 | 0.03 | 0.03 | 0.01 | — | — |
| Equity / assets | 35.1% | 68.3% | 69.0% | 96.5% | −9.5% | −1.2% |
| Jun '26 | Dec '25 | Jun '25 | Jun '24 | Dec '22 | Jun '22 | Dec '21 | Jun '21 | Dec '20 | |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & short-term investments | $363.6M | $212.5M | $317.8M | $118.8M | $116.3M | $122.6M | $22.0M | $49.6M | $77.9M |
| Cash & equivalents | $363.6M | $212.5M | $317.8M | $118.8M | $116.3M | $122.6M | $22.0M | $49.6M | $77.9M |
| Receivables | $246.0M | $207.3M | $198.7M | $97.3M | $39.4M | $16.9M | $19.4M | $365,000 | $12.4M |
| Inventory | $56.3M | $55.5M | $54.1M | $30.8M | $8.5M | $6.5M | $3.5M | $889,000 | $633,000 |
| Other current assets | $38.5M | $19.4M | $40.1M | $8.3M | $9.1M | $3.4M | $2.6M | $19.4M | $2.7M |
| Total current assets | $704.5M | $494.8M | $610.7M | $255.3M | $173.2M | $149.5M | $47.5M | $70.3M | $93.6M |
| Property, plant & equipment (net) | $187.1M | $173.2M | $113.8M | $38.3M | $18.8M | $8.5M | $6.3M | $4.6M | $4.8M |
| Goodwill & intangible assets | $843.9M | $888.1M | $896.3M | $305.9M | $64.5M | $61.8M | $59.8M | $57.9M | $63.4M |
| Long-term investments | $40.4M | $3.7M | $4.1M | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $190.0M | $211.1M | $200.9M | $146.5M | $0 | $0 | $0 | $0 | $0 |
| Total assets | $1.97B | $1.77B | $1.83B | $746.0M | $255.4M | $215.9M | $109.8M | $128.8M | $157.8M |
| Liabilities | |||||||||
| Accounts payable | $243.9M | $107.4M | $79.3M | $22.3M | $16.8M | $20.2M | $11.9M | $11.1M | $5.8M |
| Short-term debt | $22.3M | $28.0M | $32.3M | $3.8M | $1.3M | $1.1M | $632,000 | $1.1M | $767,000 |
| Deferred revenue | $562,965 | $17.2M | $6.7M | $12.4M | $3.4M | $10.2M | $6.1M | $3.0M | $3.2M |
| Total current liabilities | $349.8M | $347.0M | $458.1M | $258.4M | $85.6M | $46.5M | $38.0M | $22.3M | $20.0M |
| Long-term debt | $504.9M | $391.9M | $371.5M | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $63.5M | $62.1M | $34.1M | — | — | — | — | — | — |
| Other long-term liabilities | $407.2M | $409.7M | $348.8M | $83.6M | $92.9M | $64.0M | $68.2M | $57.6M | $64.5M |
| Total liabilities | $1.26B | $1.15B | $1.18B | $342.0M | $175.3M | $110.5M | $107.7M | $80.9M | $78.8M |
| Shareholders' equity | |||||||||
| Common stock & paid-in capital | $708.6M | $719.0M | $473.1M | $587.4M | $371.0M | $344.1M | $170.8M | $167.9M | $167.1M |
| Retained earnings (deficit) | −$160.1M | −$231.5M | −$231.7M | −$233.5M | −$272.8M | −$244.4M | −$173.5M | −$125.5M | −$93.0M |
| Accumulated other comprehensive income | $155.4M | $134.8M | $153.1M | $50.1M | −$18.1M | $5.7M | $4.8M | $5.5M | $4.9M |
| Total shareholders' equity | $704.0M | $622.3M | $647.4M | $404.0M | $80.0M | $105.4M | $2.2M | $47.9M | $79.0M |
| Key figures | |||||||||
| Total debt | $837.0M | $699.8M | $641.7M | $22.1M | $10.4M | $2.6M | $2.5M | $1.7M | $2.2M |
| Net cash (debt) | −$473.4M | −$487.2M | −$323.9M | $96.7M | $105.9M | $120.0M | $19.5M | $47.9M | $75.7M |
| Working capital | $354.6M | $147.8M | $152.6M | −$3.1M | $87.7M | $102.9M | $9.6M | $48.0M | $73.7M |
| Tangible book value | −$139.9M | −$265.8M | −$248.9M | $98.1M | $15.5M | $43.6M | −$57.7M | −$10.0M | $15.6M |
| Book value per share | $1.97 | $1.84 | $1.92 | $1.15 | $0.25 | $0.34 | $0.01 | $0.17 | $0.30 |
| Shares outstanding | 356.9M | 338.8M | 337.2M | 350.8M | 316.3M | 307.3M | 283.0M | 281.0M | 259.9M |
| Current ratio | 2.01 | 1.43 | 1.33 | 0.99 | 2.02 | 3.21 | 1.25 | 3.15 | 4.69 |
| Quick ratio | 1.74 | 1.21 | 1.13 | 0.84 | 1.82 | 3.00 | 1.09 | 2.24 | 4.53 |
| Debt / equity | 1.19 | 1.12 | 0.99 | 0.05 | 0.13 | 0.02 | 1.18 | 0.04 | 0.03 |
| Equity / assets | 35.8% | 35.1% | 35.5% | 54.2% | 31.3% | 48.8% | 2.0% | 37.2% | 50.1% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed February 20, 2026); data from EODHD.
TLX financial position
At the end of fiscal 2025 (December 31, 2025), Telix Pharmaceuticals had total assets of $1.8 billion (up 1,625.9% from a year earlier), total liabilities of $1.1 billion and shareholders' equity of $622.3 million. It held $212.5 million in cash and short-term investments against $699.8 million of debt, net debt of $487.2 million. Its current ratio was 1.43. In the latest quarter (ended June 30, 2026) total assets were $2.0 billion and equity $704.0 million.
Related: TLX income statement, TLX cash flow statement, TLX key metrics. See the TLX stock overview for the latest quote and news.
TLX balance sheet FAQ
What are Telix Pharmaceuticals's total assets?
Telix Pharmaceuticals reported total assets of $1.8 billion at the end of fiscal 2025 (December 31, 2025), compared with $102.6 million a year earlier.
How much debt does Telix Pharmaceuticals have?
Telix Pharmaceuticals had $699.8 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 1.12.
How much cash does Telix Pharmaceuticals have?
Telix Pharmaceuticals held $212.5 million in cash and short-term investments at the end of fiscal 2025; with $699.8 million of debt that is net debt of $487.2 million.
What is Telix Pharmaceuticals's book value?
Telix Pharmaceuticals's shareholders' equity (book value) was $622.3 million at the end of fiscal 2025, or $1.84 per share.
What is Telix Pharmaceuticals's current ratio?
Telix Pharmaceuticals had current assets of $494.8 million and current liabilities of $347.0 million, a current ratio of 1.43 (it can cover its short-term obligations).
How much goodwill does Telix Pharmaceuticals have?
Telix Pharmaceuticals carried $888.1 million of goodwill and intangible assets, 50.1% of total assets, at the end of fiscal 2025.